JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Clinical trial NCT06416410 · RECRUITING

Trial details

NCT number: NCT06416410
Sponsor: Allist Pharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Advanced Non-squamous Non-small-cell Lung Cancer Metastatic Non-squamous Non Small Cell Lung Cancer

Start date: 2024-08-07
Primary completion: 2029-09-30
Enrollment: 392

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.